Could live attenuated vaccines better control COVID-19?

• Published in: Vaccine 2021-09, Vol.39 (39), p.5719-5726
• Main Authors: Okamura, Shinya, Ebina, Hirotaka
• Format: Article
• Language: English
• Subjects: Adenoviruses; Antibodies; Antigens; Attenuation; Clinical trials; Coronaviruses; COVID-19; COVID-19 Vaccines; Deactivation; Disease transmission; Encephalitis; Expression vectors; Fever; Genomes; Humans; Humoral immunity; Immunity; Infectious diseases; Live attenuated vaccine; mRNA; mRNA vaccines; Pandemics; Phenotypes; Proteins; Review; SARS-CoV-2; Seeds; Severe acute respiratory syndrome coronavirus 2; Thromboembolism; Thrombosis; Vaccine; Vaccines; Vaccines, Attenuated; Viral diseases; Viruses
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2021.08.018

In an effort to control the COVID-19 pandemic, large-scale vaccination is being implemented in various countries using anti-SARS-CoV-2 vaccines based on mRNAs, adenovirus vectors, and inactivated viruses. However, there are concerns regarding adverse effects, such as the induction of fever attributed to mRNA vaccines and pre-existing immunity against adenovirus vectored vaccines or their possible involvement in the development of thrombosis. The induction of antibodies against the adenovirus vector itself constitutes another hindrance, rendering boosting vaccinations ineffective. Additionally, it has been questioned whether inactivated vaccines that predominantly induce humoral immunity are effective against newly arising variants, as some isolated strains were found to be resistant to the serum from COVID-19-recovered patients. Although the number of vaccinated people is steadily increasing on a global scale, it is still necessary to develop vaccines to address the difficulties and concerns mentioned above. Among the various vaccine modalities, live attenuated vaccines have been considered the most effective, since they closely replicate a natural infection without the burden of the disease. In our attempt to provide an additional option to the repertoire of COVID-19 vaccines, we succeeded in isolating temperature-sensitive strains with unique phenotypes that could serve as seeds for a live attenuated vaccine. In this review article, we summarize the characteristics of the currently approved SARS-CoV-2 vaccines and discuss their advantages and disadvantages. In particular, we focus on the novel temperature-sensitive variants of SARS-CoV-2 that we have recently isolated, and their potential application as live-attenuated vaccines. Based on a thorough evaluation of the different vaccine modalities, we argue that it is important to optimize usage not only based on efficacy, but also on the phases of the pandemic. Our findings can be used to inform vaccination practices and improve global recovery from the COVID-19 pandemic.